Can a simple test predict who will respond to this sarcoma drug?
NCT ID NCT04008238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use advanced testing to identify which patients are most likely to benefit, potentially leading to more personalized treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trabectedin
- What this could lead to
- If successful, this could help doctors identify which sarcoma patients are most likely to benefit from trabectedin, making treatment more personalized.
- What could go wrong
- This is a small, early-stage study focused on finding biomarkers, not on proving treatment effectiveness. The results may not apply to all sarcoma types or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOPLASTIC ROUND CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Bergonie
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can a new drug shrink Hard-to-Treat childhood cancers?
- Could a genetic marker guide future cancer therapies in taiwan?
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Experimental drug opens door for rare sarcoma patients with no options left
- Blood test may spot hidden sarcoma signals